Teva wins appeal on Cephalon drug

Fentora relieves sudden episodes of cancer pain in adults already taking opioids.

Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) announced on Friday that the US Court of Appeals for the Federal Circuit in Washington upheld the validity of a Cephalon patent on Fentora, upholding a lower court ruling that Watson Pharmaceuticals, Inc. (NYSE: WPI) infringed the patent. Fentora is approved to relieve sudden episodes of cancer pain in adults already taking opioids, or morphine-like drugs.

Watson may not market Fentora until its patent expires in 2019, subject to further appeal.

Fentora generated $81 million in US sales in the first half of 2011, Cephalon said in August. Teva acquired Cephalon in October for $6.8 billion. Cephalon develops and markets neurological and pain drugs, as well as products in the fields of asthma, oncology, stem cell, hematology, and pain.

Cephalon's main products are Provigil, which treats sleep disorders; Fentora, which treats pain; Treanda, which treats hematological cancer; and another drug that treats epilepsy.

Teva's share price rose 1.3% in early morning trading on the TASE today to NIS 151.9, after rising 1.2% on Nasdaq on Friday to $40.20, giving a market cap of $35.6 billion.

Published by Globes [online], Israel business news - - on December 11, 2011

© Copyright of Globes Publisher Itonut (1983) Ltd. 2011

View comments in rows
Update by email about comments talkback
Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018